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Abstract The early mechanisms regulating progression
towards beta cell failure in type 1 diabetes (T1D) are poorly
understood, but it is generally acknowledged that genetic
and environmental components are involved. The metabo-
lomic phenotype is sensitive to minor variations in both, and
accordingly reflects changes that may lead to the develop-
ment of T1D. We used two different extraction methods in
combination with both liquid- and gas chromatographic
techniques coupled to mass spectrometry to profile the
metabolites in a transgenic non-diabetes prone C57BL/6
mouse expressing CD154 under the control of the rat insulin
promoter (RIP) crossed into the immuno-deficient recom-
bination-activating gene (RAG) knockout (-/-) C57BL/6
mouse, resembling the early stages of human T1D. We
hypothesized that alterations in the metabolomic phenotype
would characterize the early pathogenesis of T1D, thus
metabolomic profiling could provide new insight to the
development of T1D. Comparison of the metabolome of the
RIP CD154 9 RAG-/- mice to RAG-/- mice and C57BL/
6 mice revealed alterations of [100 different lipids and
metabolites in serum. Low lysophosphatidylcholine levels,
accumulation of ceramides as well as methionine deficits
were detected in the pre-type 1 diabetic mice. Additionally
higher lysophosphatidylinositol levels and low phos-
phatidylglycerol levels where novel findings in the pre-type
1 diabetic mice. These observations suggest that metabo-
lomic disturbances precede the onset of T1D.
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1 Introduction
Type 1 diabetes (T1D) is a common chronic illness with
increasing prevalence that has serious economic conse-
quences to health care systems (Hex et al. 2012; ADA 2013;
IDF 2013). T1D is a complex, multifactorial autoimmune
disease in which the insulin-producing pancreatic beta cells
are destroyed, leaving the patient dependent on insulin
injections for sustaining life, and in risk of premature death
due to acute- and late complications (Daneman 2006). The
exact mechanisms triggering and regulating progression
towards beta cell failure in T1D development are not fully
understood. It is generally acknowledged, however, that
both genetic and environmental components are involved.
The metabolomic phenotype is sensitive to minor variations
in both, and may thus reflect changes that lead to the
development of T1D. A detailed understanding of the
pathogenesis of T1D is a prerequisite for the development
of preventive strategies. In particular, the identification of
early metabolic modifications is promising in the study of
etiological pathways and can potentially lead to the devel-
opment of biomarkers for beta cell health before clinical
symptoms appear, so that preventive strategies to save beta-
cells can be initiated. Previous studies have linked
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metabolomic disturbances to the development of T1D both
in humans and in non-obese diabetic (NOD) mice, revealing
associations between the immune system, metabolism and
the development of T1D (Oresˇicˇ et al. 2008; Sysi-Aho et al.
2011). However, it remains unclear how the immune system
interacts with the metabolome and vice versa in the T1D
disease pathogenesis.
In this study, we used a murine transgenic model that
was originally designed for the study of the initial events
leading to T1D (Haase et al. 2004; Haase and Markholst
2007). The transgenic mice express CD154 (CD40 ligand)
under the control of the rat insulin promoter (RIP) to
confine the expression to the pancreatic beta cells. In this
model, ligation of CD154 with CD40 converts an immature
and tolerogenic dendritic cell (DC) to a mature and
immunogenic DC (Bennett et al. 1998; Ridge et al. 1998;
Schoenberger et al. 1998; Grohmann et al. 2001) leading to
insulitis and diabetes development. The mice were crossed
into a recombination activating gene (RAG)-deficient
background (RAG KO). The RAG genes encodes enzymes
crucial for the generation of mature B and T cells (Nishana
and Raghavan 2012), and by introducing this genetic
modification, the authors showed that T1D development
was T- and B cell dependent, based on the observations
that the RIPCD154 9 RAG-/- mice did not develop dia-
betes as opposed to their transgene positive litter mates
RIPCD154 9 RAG-/?. Histological examinations of the
pancreas of the RIPCD154 9 RAG-/- (from here on
referred to as RIPCD154 9 RAG KO) revealed less
destructive cellular infiltrates mainly dominated by
CD11c? cells indicating that the infiltrating cells were
local DCs (Haase et al. 2004). Thus, this mouse model was
used to study the early phases of the T1D pathogenesis
defined as the non-lymphocyte-dependent initial phase
(Nerup et al. 1994) characterized by unspecific inflamma-
tion of the pancreatic islets (Eisenbarth 1986). In the pre-
sent study we used this model to characterize the
metabolomic changes preceding T1D, without the influ-
ence of the adaptive immune system. We compared the
RIP CD154 9 RAG KO mice to RAG KO mice and
C57BL/6 control mice to reveal early metabolomic alter-
ations without the immune component, to elucidate the
mechanisms leading to T1D. With the recent advances in
high throughput mass spectrometry based technologies, it
is now possible to achieve thorough metabolomics inves-
tigation of fluids, such as serum, and tissue (Zhang et al.
2014a). We aimed at investigating differences in the serum
metabolome using a single phase extraction method com-
bined with a targeted lipidomic approach by liquid chro-
matography electrospray ionization tandem mass
spectrometry (LC ESI–MS/MS) and furthermore, a polar
metabolite profiling through gas chromatography mass
spectrometry (GC–MS), where the resultant data was
analysed using targeted and untargeted data processing
methodologies. Using two different mass spectrometry
based strategies for in-depth characterization of this murine
model revealed metabolomic insight into the disease
pathogenesis in the early stages leading to T1D, and
identified metabolites with the potential to be developed
into future biomarkers of beta cell health.
2 Materials and methods
2.1 Animals
Both transgenic (RIP-CD154 9 RAG KO (n = 6) and
RAG KO (n = 3) on a C57BL/6 background) and control
mice (C57BL/6) (n = 10) were bred at Taconic M&B, Ry,
Denmark, and genotyped by PCR as previously described
(Haase et al. 2004; Haase and Markholst 2007). The ani-
mals, all female and 12 weeks old, were housed in poly-
ethylene cages in a temperature, humidity and 12 h day–
night rhythm controlled room receiving standard chow.
After weighing of the animals, blood samples were col-
lected retro-orbital, without anesthesia, into eppendorf
tubes and the animals sacrificed immediately afterwards.
The blood samples were left for coagulation and hereafter
centrifuged (15 min at 20009g at RT) for the collection of
serum. Blood glucose was measured in serum using the
Accu-Chek Aviva system by Roche. All animal experi-
ments were conducted according to Danish legislation and
approved by the Danish Animal Inspectorate.
2.2 Lipidomics
Samples were randomized and lipids extracted from serum
(10 lL) using a single phase chloroform methanol (2:1)
method following addition of 15 internal standards (sup-
plementary Table 3), as described in detail previously (Weir
et al. 2013). Lipid analysis was performed using an Agilent
1200 liquid chromatography system coupled to an Applied
Biosystem API 4000 Q/TRAP mass spectrometer with a
turbo-ionspray source and Analyst 1.5 data system. Over
300 species of lipid were analysed including species of:
dihydroceramide (dhCer), ceramide (Cer), monohexosylce-
ramide (MHC), dihexosylceramide (DHC), trihexosylce-
ramide (THC), GM3 ganglioside (GM3), sphingomyelin
(SM), phosphatidylcholine (PC), alkylphosphatidylcholine
(PC(O)), alkenylphosphatidylcholine (plasmalogen, PC(P)),
lysophosphatidylcholine (LPC), lysoalkylphosphatidyl-
choline (lysoplatelet activating factor, LPC(O)), phos-
phatidylethanolamine (PE), alkylphosphatidylethanolamine
(PE(O)), alkenylphosphatidylethanolamine (plasmalogen
(PE(P)), phosphatidylinositol (PI), lysophosphatidylinositol
(LPI), phosphatidylserine (PS), phosphatidylglycerol (PG),
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free cholesterol (COH), cholesteryl ester (CE), diacylglycerol
(DG) and triacylglycerol (TG) using multiple reaction mon-
itoring (MRM) experiments, described previously (Meikle
et al. 2013; Weir et al. 2013). The abbreviations listed here
refer to the lipid classes and subclasses, the number of carbons
and double bonds will be listed when referring to individual
lipid species, such as LPC 22:6 which define a lysophos-
phatidylcholine containing a fatty acid comprising 22 carbon
atoms and six double bonds. Lipids composed of two fatty
acids are determined as the sum of the carbons and the double
bonds across both fatty acids, e.g. PC 36:4 as described pre-
viously (Meikle et al. 2013). Relative concentrations of lipid
classes and subclasses were calculated from the sum of the
individual lipid species within each class.
2.3 Polar metabolomics
Serum samples and nine pooled (an aliquot of all the
samples) quality control samples incorporated into the
analysis sequence, were extracted in a 1:3:1 (v/v/v) ratio of
chloroform:methanol:water, where 20 lL serum was
regarded as the water phase. Briefly, 20 lL chloroform was
added to the serum and vortexed to mix, followed by the
addition of 60 lL methanol [containing internal standards;
13C-sorbitol (16.6 lM) and 13C,15N-valine (166 lM),
Sigma], vortexed, then allowed to incubate on ice for
10 min. Samples were then centrifuged for 5 min at
14000 rpm at 4 C to pellet precipitated proteins and the
supernatant transferred to a fresh tube. Next 40 lL Milli-Q
water was added to the supernatant to bring the solvent
ratio to 1:3:3 (v/v/v) chloroform:methanol:water, thereby
enabling biphasic partitioning of the extract. After vor-
texing, samples were centrifuged to clearly separate the
aqueous (methanol/water) and organic layers (chloroform).
60 lL of the upper aqueous layer containing polar
metabolites was taken and evaporated to complete dryness
in vacuo. The extraction protocol was modified from the
Bligh-Dyer protocol from 1957 (Bligh and Dyer 1959).
Polar metabolites were derivatised online using a Ger-
stel MPS2 XL autosampler robot (Gerstel, Germany).
Samples were first methoxyaminated by the addition of 20
lL methoxyamine (30 mg/mL in pyridine, 2 h, 37 C,
750 rpm), followed by trimethylsilylation with 20 lL
BSTFA ? 1 % TMCS (1 h, 37 C, 750 rpm). Metabolite
profiles were acquired on an Agilent 7890A Gas Chro-
matograph coupled to a 5975C Mass Selective Detector,
where 1 lL of derivatised sample was injected into a split/
splitless inlet set at 250 C. Chromatographic separation
was achieved using a J&W scientific VF-5 ms capillary
column (30 m 9 0.25 mm 9 0.25 lM ? 10 m dura-
guard). Oven conditions were set at 35 C starting tem-
perature, held for 2 min, then ramped at 25 C/min to
325 C and held for 5 min. Helium was used as the carrier
gas at a flow rate of 1 mL/min. Compoundswere fragmented
by electron impact (EI) ionization and detected across a m/z
range of 50–600 amu, with a scan speed of 9.2 scans/s. The
metabolomics data was analysed using a targeted and an
untargeted approach. For the untargeted profiling, chro-
matograms were processed using PyMS (O’Callaghan et al.
2012) to align metabolites and quantify a representative
target ion, and subsequently generate a data matrix. For
targeted profiling, chromatograms were processed using
Agilent’s Mass Hunter Quantitative Analysis software,
where target ion areas for polar metabolites contained within
the in-house Metabolomics Australia (MA_25C) metabolite
library were integrated and output as a data matrix for
downstream data analysis. Each detected metabolite was
visually inspected and manually integrated if required. This
resulted in a highly curated matrix representing the detected
metabolites in each sample.
2.4 Data analysis
Animals weight and blood glucose was compared between
groups using Kruskal–Wallis analysis using MatLab,
MathWorks.
2.4.1 Lipidomics
Peak integration of both internal standards and serum
samples was performed using the MultiQuantTM, Sciex,
software with manual inspection as required. Relative
concentrations of the lipids were calculated automatically
based on the internal standards. Lipids with relative con-
centrations not exceeding three times the background noise
in five or more of the analyzed samples were excluded for
further analysis.
2.4.2 Normalization of lipid data
Serum lipids were normalized to total content of PC (rel-
ative concentration of individual lipid specie/relative con-
centration of total PC) within the sample to allow for
differences in hydration level of individual mice. This
resulted in decreased variance within mouse groups and
improved statistical power. We use phosphatidylcholine
(the most abundant phospholipid class) as an internal ref-
erence to assess the relative differences in plasma com-
position between mouse strains.
2.4.3 Statistical analysis
Serum lipid relative quantities were analyzed, individually
and divided into lipid classes, using Kruskal–Wallis anal-
ysis. p values were corrected for multiple comparisons
using the Benjamini–Hochberg method. p values were
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considered significant \0.05 and all statistical analysis
were performed in SPSS from IBM, MatLab or R.
2.4.4 Polar metabolomics
After median normalization of the targeted metabolomics
data, the serum samples from the three groups were ana-
lyzed by Kruskal–Wallis test using the Benjamini–Hoch-
berg method to correct for multiple testing. Post-hoc, pair
wise analyses were performed using the Mann–Whitney U
test, and the resultant pair wise p values were corrected by
the Dunn–Sidak approach using MatLab. The untargeted
data was statistically analysed similarly.
3 Results and discussion
3.1 Characteristics of the animals
The three different groups of animals were well matched
regarding age (all were 12 weeks), but varied in weight and
blood glucose (Table 1). The RIP CD154 9 RAG KO
mice had higher blood glucose levels compared to the RAG
KO and control mice. This is in agreement with previous
reports, where significant fluctuations in blood glucose
over a time period of 40 weeks was recorded in this model
(Haase et al. 2004; Haase and Markholst 2007). The
authors explained this by insufficient ability of the beta-
cells to produce the required insulin amounts to preserve
blood glucose homeostasis, because of the local DC infil-
tration of the islets.
3.2 Lipid measurements
3.2.1 Reproducibility of the assay
To assess the assay performance of the entire procedure six
quality control (QC) human plasma pool samples were
evenly integrated in the extraction process amongst the
serum samples from the animals, and were analyzed
accordingly with the MRM method. The median intra-run
coefficient of variation (% CV) was 5.88 % (supplemen-
tary Table 1).
3.2.2 Identification and quantification of lipids in serum
A total of 351 lipids from 21 different lipid classes and
subclasses were identified in the serum of the murine
models and relative quantities of these were compared
between the RIP CD 154 9 RAG KO, RAG KO and
control mice (supplementary Table 1). We compared the
RIP CD154 9 RAG KO mice to RAG KO mice also to
identify early metabolomic alterations, without the immune
component, as we anticipated that the RAG KO model
would be the best suited control in regards to the transgene
element of the model.
Among the most striking differences in the overall lipid
classes and subclasses were the LPCs, DHCs, LPI, PG and
CEs (compared by ANOVA, p\ 0.05 after Benjamini–
Hochberg correction, Table 1). The LPCs were present in
lower amounts in the RIP CD154 9 RAG KO and RAG
KO mice compared to control with the lowest levels found
in the RIP CD154 9 RAG KO. The shorter chain LPC’s
(\18 C) were significantly reduced in the RIP
CD154 9 RAG KO mice compared to the control mice,
but not RAG KO mice (sup Table 1). LPC differences in
relation to progression to T1D have previously been
identified in NOD mice (Sysi-Aho et al. 2011). In a subset
of NOD mice negative for insulin antibodies (IAA) but
later developing T1D, marginal higher levels of LPC were
found as compared to NOD IAA negative animals that did
not progress to T1D (Sysi-Aho et al. 2011). The latter
group is comparable to our model in terms of lack of
antibodies and non-progression to T1D and accordingly our
results follows these prior observations (Sysi-Aho et al.
2011). Clinical research has also revealed changes in LPCs
according to T1D progression. Oresic and coworkers
identified transiently elevated overall serum LPC levels in
children who later developed T1D (Oresˇicˇ et al. 2008) and
a 1.3–1.5 fold increase in the LPC (18:0/0:0) prior to
seroconversion. Our results revealed higher levels of the
LPC 18:0 (sup Table 1) in the RIP CD154 9 RAG KO
mice compared to the RAG KO mice and control. A recent
study indicates that the LPCs have dual functions; they are
capable of activating TLR4 and TLR2-1 mediated proin-
flammatory signaling, but in the presence of classical TLR
ligands, the LPCs counteract some of the TLR mediated
responses and overall induce an anti inflammatory envi-
ronment (Carneiro et al. 2013). Overall it seems reasonable
to speculate that LPCs might have different roles in each
stage of the T1D disease pathogenesis. Low levels of LPCs
in childhood have been linked to the transport of choline to
tissues (Croset et al. 2000), and choline deficiencies have
been associated to the development of T1D (Oresˇicˇ et al.
2008). Later in the disease process, LPC may act as
immune modulators through the lysophosphatidylcholine
receptor an immunoregulatory G protein-coupled receptor
named G2A whose genetic ablation resulted in the devel-
opment of inflammatory autoimmune disease (Kabarowski
et al. 2002).
Total serum CE levels differed between the groups of
mice, with the lowest level found in the RIPC-
D154 9 RAG KO mice. Previous research in the esterifi-
cation of cholesterol in type 1 diabetic patients has
revealed a lower esterification percentage of cholesterol in
the very low density lipoprotein (VLDL) and intermediate
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density lipoprotein (IDL) compared to that of control
subjects and a general increase in cholesterol absorption
(Gylling et al. 2004). The RIP CD154 9 RAG KO mice
had borderline significant higher free cholesterol (COH)
levels compared to control, but the overall difference
between groups were not significant after correction for
multiple comparison. Previous research on CE synthesis in
relation to atherosclerosis in T1D in humans revealed an
accumulation of CE in macrophages incubated with low
density lipoproteins (LDL) from T1D patients compared to
LDL from control, and a parallel higher accumulation of
CE in the T1D patients. The authors also found that the
non-enzymatic glycosylation of LDL in the T1D patients
were higher and correlated with the CE synthesis. The
glycosylation is possibly explained by the higher blood
glucose in T1D patients, and this may in general contribute
to the acceleration of atherosclerosis seen in diabetic
patients (Lyons et al. 1987). This is in contradiction to our
results, but may be a consequence of the transgenic mice
not being able to produce mature macrophages because of
the knock out of the RAG genes.
Total levels of DHC varied considerably (p\ 0.05)
among the three different types of mice (Table 1) with
lower levels detected in control mice. DHC as well as
MHC and THC are metabolites of Cer and the precursor
dhCer. The two transgenic models had generally higher
levels of the three metabolites compared to control mice. In
the RIP CD154 9 RAG KO mice the dhCer and Cer levels
were in general higher in comparison to the RAG KO mice
but the metabolites of the ceramides were lower, except for
DHC. This particular expression pattern of the ceramides
and its metabolites has been observed previously in two
cohorts of pre-type 2 diabetic patients, where up regulation
of de novo ceramide synthesis were not reflected in the
downstream metabolites of ceramide (Meikle et al. 2013).
Studies on streptozotocin induced T1D mice also showed
Table 1 Percentage change of weight, blood glucose and lipids by class from control C57BL/6
RIP CD 154 9 RAG KO
(n = 6) change in % from control
RAG KO (n = 3)
change in % from control
Weight* 3.5 11.8
BG serum* 102.67 6.69
Dihydroceramide (dhCer)*,# 77.78 77.78
Ceramide (Cer)*,# 29.22 22.73
Monohexosylceramide (MHC) 20.84 38.41
Dihexosylceramide (DHC)**,# 50 37.5
Trihexosylceramide (THC) 0 50
GM3 ganglioside (GM3) -18.18 9.09
Alkylphosphatidylcholine (PC(O)) -8.15 -7.45
Sphingomyelin (SM) -0.32 16.53
Alkenylphosphatidylcholine (plasmalogen, PC(P)) 0.19 14.53
Lysophosphatidylcholine (LPC)**,# -15.39 -4.16
Lysoalkylphosphatidylcholine (lysoplatelet activating factor, LPC(O)) -12.35 8.64
Phosphatidylethanolamine (PE) 9.02 -11.22
Alkylphosphatidylethanolamine (PE(O))*,# 28.42 40.7
Alkenylphosphatidylethanolamine (plasmalogen PE(P))* 16.77 35.98
Lysophosphatidylethanolamine (LPE)# 13.72 21.27
Phosphatidylinositol (PI) 2.43 16.79
Lysophosphatidylinositol (LPI)**,# 26.02 58.86
Phosphatidylserine (PS) -28.89 -6.11
Phosphatidylglycerol (PG)**,#,$ -33.33 -50
Free cholesterol (COH)* 12.11 28.38
Cholesteryl ester (CE)**,# -19.73 -9.5
Diacylglycerol (DG) 22.98 -13.13
Triacylglycerol (TG) -7.45 -49.6
* p\ 0.05 in the KW comparison
** p\ 0.05 after Benjamini–Hochberg correction
# p\ 0.05 in RIP CD154 9 RAG KO versus control
$ p\ 0.05 in RAG KO versus control
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accumulations of ceramides in the muscles of the animals
after one week of insulin deprivation (Zabielski et al.
2014). Ceramides are found in high concentrations within
the cell membranes and the membranes of the organelles,
and the composition of the ceramides has been suspected to
affect the function of the organelles. Recent advances in
technology has facilitated investigating the role of cer-
amides in beta-cell dysfunction, and the current debate on
ceramides role in T1D focuses on whether ceramides can
mimic the effects of IL-1b in promoting beta-cell death and
in repressing insulin production, reviewed in the paper by
Boslem et al. (Boslem et al. 2012).
Interestingly, we also detected differing levels of LPI
and PG in the comparison of all three groups of mice.
Significant higher levels of LPI and lower levels of PG
were seen in RIP CD154 9 RAG KO compared to control
mice. LPI affects numerous functions such as cell growth,
differentiation and motility in a number of different cell-
types through the orphan G protein-coupled receptor
GPR55 specific receptor for LPI (Pin˜eiro and Falasca
2012). The LPIs and their receptors have been implicated
in both physiological and pathophysiological processes
such as autoimmune diseases and inflammation (Kihara
et al. 2015). PGs are primarily confined to the mitochondria
where they support membrane structure and functions as a
substrate for the synthesis of cardiolipin (Zhang et al.
2014b). Cardiolipin is an important component of the inner
mitochondrial membrane, and is particularly susceptible to
attacks of reactive oxygen species (ROS) leading to the
formation of cardiolipin peroxidation that can activate
apoptosis (Paradies et al. 2009). To our knowledge no
previous studies have addressed the role of these lipids in
diabetes; consequently future studies are needed to inves-
tigate their potential role in the early stages of T1D.
3.3 Polar metabolomics
3.3.1 Reproducibility of the metabolomic analysis
The reproducibility of the method was assessed by incor-
porating nine pooled quality control samples throughout
the analysis sequence. The median % CV was 17.85 of the
analytes (Table 2). All metabolites with CV[20 % were
inspected manually, and were identified as compounds
found in very low abundance.
3.3.2 Identification and relative quantification
of metabolites in serum
To determine if there were metabolic differences between
these sample groups, a broad profiling metabolomics
analysis was undertaken using the GC–MS to detect polar
metabolites. Statistical analysis (PCA) of the 213
metabolites detected showed separation between the sam-
ple groups (not shown) and univariate analysis revealed
that 78 of the 213 metabolites were significantly different
between the group (p\ 0.05 after Benjamini–Hochberg
correction, supplementary Table 2). To explore the meta-
bolomics data further, metabolites were subjected to data-
base searches using in-house standards and NIST libraries
which resulted in the identification of 56 metabolites of
which 18 metabolites varied significantly p\ 0.05 (after
Benjamini–Hochberg correction) (Table 2), and were
dominated by amino acids and their derivates and simple
carbohydrates. 13 out of 23 amino acids and their deriva-
tives varied significantly between the groups, with the
lowest levels seen in the RIP CD154 9 RAG KO mice,
except for L-isoleucine, L-ornithine an L-tyrosine, where the
lowest levels were observed in the RAG KO model
(Table 2). Differences in the amino acid metabolites have
been observed previously in children at risk for developing
T1D, especially lower methionine levels were seen in
children who developed autoantibodies at two years old
compared to children who developed autoantibodies later
in childhood or remained autoantibody negative (Pflueger
et al. 2011). L-Methionine relative concentration was
decreased in the RIP CD154 9 RAG KO mice compared
to RAG KO and control (Table 2). It is known that
methionine is involved in numerous metabolic processes
including the catabolic pathway of choline and serves as a
precursor for other sulfur containing amino acids such as
taurine (Pflueger et al. 2011). Taurine levels were
decreased in RIP CD 154 9 RAG KO and RAG KO
compared to control, however not significantly after cor-
recting for multiple comparisons (Table 2). Lower levels of
taurine in plasma in T1D patients has previously been
shown compared to control individuals (Franconi et al.
1995), and it is generally accepted that taurine has a
cytoprotective function (Ito et al. 2012). Studies in preg-
nant wistar rats revealed that taurine supplementation to a
low protein diet could reverse the effects of the low protein
diet on the fetuses during gestation. The reduction in pro-
tein intake during pregnancy mainly targeted the beta-cells
respiratory capacities in the fetuses, leaving the cells more
vulnerable to high glucose levels and more sensitive to
proapoptotic cytokines. Taurine supplementation of the
maternal diet abolished the effect of the low protein diet in
the fetuses, possibly through mediation of the mitochon-
drial metabolism (Reusens et al. 2008). The formation of
taurine is based on methionine and involves a trans-
methylation. This reaction has previously been suggested
to play a role in the T1D pathogenesis, because the turn-
over of methionine by transmethylation is fourfold higher
than protein degradation and synthesis, and methionine is
essential for lymphocyte proliferation (Pflueger et al.
2011). In our data, the L-methionine levels are lower in the
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Table 2 Percentage change, and coefficient of variation, from control C57BL/6, of polar metabolites in serum
Biochemical pathway Metabolite % CV RIP CD154 9 RAG KO
(n = 6) % change
RAG KO
(n = 3) % change
Amino acids and derivatives L-Alanine*,# 22.97 -47.37 -37.51
L-Valine**,# 2.47 -37.28 -37.06
L-Leucine* 4.6 -35.64 -34.27
L-Isoleucine**,# 8.82 -35.06 -35.98
L-Threonine**,# 3.87 -52.48 -41.79
L-Proline**,# 7.93 -53.44 -43.30
Glycine* 13.03 -23.76 -20.98
L-Serine**,# 5.88 -41.17 -29.30
Beta-alanine* 12.11 -11.24 -16.85
DL-homoserine**,# 22.55 -57.14 -50.00
L-Aspartic acid**,# 15.33 -50.54 -11.83
Trans-4-hydroxyl-L-proline 17.86 -29.37 -27.78
L-Methionine**,# 17.84 -66.9 -49.8
Pyroglutamic acid**,# 17.61 -38.75 -24.78
L-Phenylalanine**,# 23.08 -60.02 -46.77
Taurine* 58.84 -41.34 -74.56
L-Ornithine**,# 30.30 -71.73 -73.25
L-Lysine**,# 21.94 -68.27 -48.48
Adenine 46 -45.45 27.27
L-Tyrosine**,# 10.07 -59.57 -60.80
L-Tryptophan 20 -25.99 -33.55
5-Oxoproline* 17.86 139.36 196.58
Putrescine*,# 40.16 -46.15 -30.77
Citric acid cycle Succinate 13.98 -33.62 -23.28
Fumarate 5.43 -42.64 -27.13
Cis-aconitate 21.22 -41.67 -25.00
Citriate 2.92 -24.87 -24.37
Isocitrate 4.6 -27.59 -26.44
L-Malic acid 1.68 -41.02 -20.68
Carbohydrate D-Erythrose 25.39 14.29 -42.86
Meso-erythritol**,$ 3.83 10.00 -26.67
D-Ribose 15.36 -21.48 46.31
D-Fructose**,# 43.5 287.44 -14.08
D-Talose 138.08 116.54 -55.97
Sucrose 5.55 -50.00 -19.57
D-Maltose**,# 8.21 183.33 8.33
Trehalose**,# 11.47 137.50 -18.75
Glycolysis D-(-)-3-phosphoglyceric acid 43.22 -50.00 -25.00
Fructose-6-phosphate 47.69 27.08 -25.00
Glucose-6-phosphate 44.59 38.24 -30.88
Uridine 21.3 9.76 7.32
Fatty acids Tetradecanoic acid**,# 37.62 129.01 -35.50
Hexadecanoic acid (palmitic acid)* 4.22 -12.85 -46.04
Octadecanoic acid (stearic acid)*,# 47.69 54.15 3.56
Organic acid Benzoic acid 5.24 1.85 -7.41
Glyceric acid 40.22 3.42 -26.50
N-acetyl-L-glutamic acid 29.9 0.00 -25.00
D-Gluconic acid 32.40 15.38 -30.77
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transgene mice compared to control, but since the two
transgenic models don’t produce lymphocytes, this rela-
tionship might not be relevant. In contrast to previous
research, the branched chain amino acids, L-leucine,
L-isoleucine and L-valine, were found in lower levels in the
two genetically modified models, Oresic et al. found the
branched chain amino acids increased before seroconver-
sion in children progressing to T1D (Oresˇicˇ et al. 2008).
Four out of eight simple carbohydrates differed signifi-
cantly between the groups, with biggest differences seen in
fructose (Table 2). We found the highest level of D-fructose
in the RIP CD154 9 RAG KO mice, and this is in agree-
ment to an older study where higher levels of monosac-
charides were detected in diagnosed T1D patients
(Pitka¨nen 1996). The intermediates in both the glycolysis
and the citric acid cycle along with several organic acids
did not vary between the groups of mice.
4 Conclusions
This profiling study provides further explanation to the
metabolomic changes seen in the early stages of T1D.
Many of our findings confirm previous results such as low
LPC levels, accumulation of ceramides and methionine
deficits in the development of T1D. Of special interest is
the increased level of LPI and decreased level and PG seen
in the RIP CD154 9 RAK KO mice, both lipid classes
involved in cell signaling and previously linked to
autoimmune diseases. Further mechanistic studies are
needed in these lipids to elucidate their potential role in the
T1D pathogenesis.
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